Evidence map›Paper›PMID 33305610›Full record

ArticlePharmacogenomics2021

Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in

Tristan M Sissung, Lisa Cordes, Cody J Peer, Shruti Gandhy, Jason Redman, Julius Strauss, William D Figg

Abstract readCase Reports
In one paragraph

Article in Pharmacogenomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tristan M SissungClinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0002-3684-5377
Lisa CordesGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0003-3833-4084
Cody J PeerClinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0001-9395-3473
Shruti GandhyGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Jason RedmanGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0001-8200-0167
Julius StraussLaboratory of Tumor Immunology & Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0002-7550-4938
William D FiggClinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.ORCID 0000-0003-2428-5613

Funding

Clinical PharmacogeneticsZIABC010627 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$13.9M
Cancer Immunotherapy Clinical TrialsZIABC011547 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STRAUSS, JULIUS · 2014 to 2023
$8.1M
Intramural NIH HHS ZIA BC010627NCI NIH HHS ZIA BC 010627
6 · The paper itself

Abstract

Cancers of the colon are commonly treated with fluoropyrimidines, which often cause severe toxicities in patients with certain variants in

Indexed as

AllelesAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBlack or African AmericanColorectal NeoplasmsDihydrouracil Dehydrogenase (NADP)FemaleFluorouracilHeterozygoteHumansLeukocyte CountMiddle AgedPolymorphism, GeneticAntimetabolites, AntineoplasticDihydrouracil Dehydrogenase (NADP)Fluorouracil

Identifiers

PMID33305610
PMCPMC7831885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.